Purpose or Objective:
In patients with inoperable stage I non-small cell lung cancer (NSCLC) or for those refusing surgery, stereotactic body radiotherapy and particle radiotherapy have become therapeutic options. We conducted a Phase I/II study on single-fraction carbon ion radiotherapy (SF-CIRT) for stage I NSCLC that yielded a 3-year survival rate of 75.5% for 218 patients. Until now, the effect of hypofractionated CIRT on pulmonary function (PF) has not been well documented. The purpose of this study was to assess the long-term impact of SF-CIRT on PF in stage I NSCLC patients.
Material and Methods:
A review of prospectively collected data from SF-CIRT-treated patients was performed. Patients underwent PF tests (PFT) (or: underwent a PF test) immediately before, and at 6, 12, and 24 months after irradiation. Patients who relapsed or needed adjuvant treatment were excluded as these events might affect PF.
Results:
Forty patients treated between 2007 and 2012 fulfilled the inclusion criteria. According to the dose escalation study protocol, a median prescribed single-fraction dose of 46 GyE (range, 44-50 GyE) was delivered. All treatment-related complications were self-limited, without any grade 3-5 toxicities. Two years post-CIRT, the mean values of forced expiratory volume in 1 sec (FEV1) [-8 .4% ± 11.9% (p < 0.001)] and the FEV1 per unit of forced vital capacity (FEV1/FVC) [-8 .9% ± 11.7% (p < 0.001)] were less than the pre-CIRT values. There were no significant overall changes in total lung capacity, vital capacity, FVC, and residual volume before SF-CIRT and 2 years after SF-CIRT. At 6 months post-treatment, the diffusion capacity of the lung for carbon monoxide (DLCO) was significantly less than the pretreatment value (86.7 ± 32.7% vs. 78.1 ± 31.1%; p = 0.002); however, at 24 months post-treatment, the mean DLCO recovered to pretreatment levels (86.9 ± 30.5%). This might have been due to recovery from non-symptomatic radiation pneumonitis and/or smoking cessation.
Conclusion:
We found stage I NSCLC patients had good longterm preservation of PF after SF-CIRT. Follow-up PFT revealed the following: Declines in FEV1 and FEV1/FVC were statistically significant but clinically trivial, DLCO decreased temporary, thereafter it tended to recover to pretreatment levels within 2 years.
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Material and Methods: 93 patients (54F [58%], 39M [42%])
aged from 3 (6 children) to 77 (median 48) treated for thymic tumors since 1981. 84 patients (90%) were diagnosed with thymoma, 9 (10%) with thymic carcinoma. Masaoka stage was assessed in 93% (56% stage II, 31%-III, 6%-IV). All patients were irradiated. In 76 cases radiotherapy (RT) followed surgery -in 41 patients after radical and in 35 after incomplete resection. In 17 cases RT was definitive treatment, combined in 14 patients with chemotherapy. Patients were irradiated with fraction dose of 1.1-4.0Gy (median 2.0) to the total dose of 20-68Gy (median 49.5). Patient-and treatment-related factors potentially affecting survival and local control (LC) were evaluated with log-rank test. Survival analysis was performed with Kaplan-Meier method.
Results: Tumors relapsed in 17 patients. Metastases occurred after 6-129months (median 10.1) in 12 patients (in 8 in lungs). During the follow-up 17 patients died due to progression(13) or recurrence(4) of the disease. Median overall survival (OS) in the whole group (since diagnosis) was 140.2months. OS was significantly longer in patients with WHO B1 type(p = 0.02), in good performance status (PS)(p = 0.0005), without radiation-induced pulmonary fibrosis(p= 0.02) or second cancer(p= 0.03). Difference in OS between patients treated with radical surgery+RT, nonradical surgery+RT and definitive RT was of borderline significance(p = 0.065). Factors significantly decreasing LC were: male sex(p = 0.04), WHO B2 type(p = 0.01), bad PS(p= 0.0007), presence of metastases(p= 0.003) and second cancer(p=0.03).
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Conclusion:
Obtained results do not permit to form robust conclusion concerning role of RT in the management of thymic tumors patient. Besides clear, unquestionable bad prognostic factors as bad PS, low differentiation, presence of local relapse, lung fibrosis, second malignancy or distant metastases, we found only one more -male sex, decreasing LC. To determine whether this benefit persisted with contemporary standards of staging and systemic therapy, we studied the outcomes of patients with locally advanced/metastatic NSCLC receiving palliative radiotherapy in our centre over a 2 year period.
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Material and Methods:
The case records of 176 patients who received palliative thoracic radiotherapy in 2011 or 2012 were reviewed retrospectively. Data collected included age, stage, performance status, dose/fractionation, additional treatments and survival.
Results: 36 patients received high dose thoracic radiotherapy (HDTRT, 36-40 Gy in 12-15 fractions) and 140 received a lower dose (LDTRT), 20 Gy in 5 fractions. Median OS in the HDTRT group was 8.5 months and 5.5 months in the LDTRT group (hazard ratio 0.6, p <0.01). 12 patients received chemotherapy and HDTRT with median OS 12m vs 7m in the 25 patients receiving chemotherapy and LDTRT. In those who received HDTRT alone, median OS was 6.5m vs 4m for LDTRT alone. In patients with stage II-III disease median OS was 9.6m vs 6m for LDTRT. In those with stage IV disease, median OS was 8m for HDTRT vs 5m for LDTRT. In patients with performance status 0-2 median OS was 9m for HDTRT vs 6m for LDTRT, while in the two patients with performance status 3 who were irradiated it was 1m with HDTRT vs 3m with LDTRT.
Conclusion:
This audit of contemporary practice suggests that the survival benefit of high dose palliative radiotherapy reported by Macbeth (Clin Oncol (R Coll Radiol). 1996; 8:167-75) persists with modern staging and systemic therapy practices, and may also extend to patients with small volume stage IV disease excluded from that trial, but not those with poor performance status. (PC) after SBRT make it difficult the differential diagnosis between treatment effects and disease recurrence. The purpose of our study was to identify the radiographic features (High Risk Features: HRFS) with high specificity (SP) and sensitivity (SE) for early detection of recurrence.
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